Successful Exit: Shimadzu Corporation acquires majority stake in deep-tech startup Plasmion

Japanese provider of analytical instruments acquires 75% of shares; founders remain significantly invested

Munich, 29 April 2026 – The Augsburg-based deep-tech startup Plasmion has reached a major milestone in its growth with the investment by Shimadzu Corporation: the Japanese manufacturer of analytical instruments is acquiring a 75% stake, bringing not only capital but also global sales strength and industrial scaling expertise. BayBG invested in Plasmion in 2019 alongside High-Tech Gründerfonds (HTGF) and has supported the company’s development throughout its growth journey.

At the core of the transaction is Plasmion’s patented SICRIT® (Soft Ionization by Chemical Reaction In Transfer) technology, an innovative ion source for mass spectrometers. It enables highly sensitive, real-time analysis of substances directly from ambient air—without complex sample preparation. The technology is already in use in analytical laboratories, including applications in the medical, pharmaceutical, and food industries.

With Shimadzu, Plasmion gains a global leader in analytical measurement and diagnostic systems, particularly in the fields of mass spectrometry, chromatography, and medical technology. The existing collaboration between the two companies, ongoing since 2019, is now being strategically expanded: SICRIT is set to be integrated into Shimadzu’s established platforms, a move expected to significantly accelerate market adoption.

“The combination of Plasmion’s technology and Shimadzu’s global reach creates ideal conditions for the next phase of growth,” says Andreas Heubl, Senior Investment Manager at BayBG Venture Capital. “We wish Dr. Thomas Wolf, Dr. Jan-Christoph Wolf, and their team continued success and all the best.”

About BayBG Venture Capital
For more than 25 years, BayBG Venture Capital has been supporting innovative technology startups in Bavaria on their growth journey. During this period, the firm has invested €200 million in more than 80 companies. BayBG Venture Capital operates with an evergreen structure, enabling it to offer founder-friendly insttitutional Venture Capital and Venture Debt without the constraints of traditional fund structures. Depending on the stage of the company, initial investments typically range from €1 million (late seed) to €5 million (Series A/B).

For more information, please visit: www.baybg-vc.de

*SICRIT is a registered trademark of Plasmion.